Manning & Napier Advisors LLC Acquires 92,270 Shares of Cellebrite DI Ltd. $CLBT

Manning & Napier Advisors LLC boosted its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 156.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 151,320 shares of the company’s stock after purchasing an additional 92,270 shares during the quarter. Manning & Napier Advisors LLC owned about 0.06% of Cellebrite DI worth $2,804,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in CLBT. Financial Management Professionals Inc. bought a new stake in shares of Cellebrite DI in the 3rd quarter worth approximately $28,000. CWM LLC boosted its holdings in Cellebrite DI by 85.7% in the third quarter. CWM LLC now owns 1,560 shares of the company’s stock worth $29,000 after acquiring an additional 720 shares in the last quarter. Signaturefd LLC grew its stake in shares of Cellebrite DI by 68.3% in the second quarter. Signaturefd LLC now owns 2,019 shares of the company’s stock worth $32,000 after acquiring an additional 819 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Cellebrite DI by 1,998.0% in the second quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company’s stock worth $34,000 after acquiring an additional 1,998 shares during the last quarter. Finally, Toth Financial Advisory Corp bought a new position in shares of Cellebrite DI during the third quarter valued at $38,000. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Cellebrite DI Stock Down 2.5%

Shares of Cellebrite DI stock opened at $17.55 on Thursday. Cellebrite DI Ltd. has a twelve month low of $13.10 and a twelve month high of $26.30. The company’s 50 day moving average is $17.86 and its 200 day moving average is $16.92. The company has a market cap of $4.20 billion, a price-to-earnings ratio of 56.61, a price-to-earnings-growth ratio of 2.51 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings results on Wednesday, November 12th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05). Cellebrite DI had a return on equity of 20.81% and a net margin of 16.74%.The firm had revenue of $126.03 million during the quarter, compared to analysts’ expectations of $122.98 million. During the same quarter last year, the business earned $0.14 earnings per share. The business’s quarterly revenue was up 17.9% on a year-over-year basis. Sell-side analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. JPMorgan Chase & Co. increased their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. Needham & Company LLC upped their target price on shares of Cellebrite DI from $22.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Bank of America raised their price target on shares of Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Lake Street Capital boosted their price objective on shares of Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Finally, Wall Street Zen cut Cellebrite DI from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $24.00.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.